

# Infrequent fractures and resilient bone mineral density: bone health in patients with Fanconi anemia

Jane Koo,<sup>1,2</sup> Jonathan C. Howell,<sup>2,3</sup> Lindsey Hornung,<sup>4</sup> Anthony Sabulski,<sup>1,2</sup> Parinda A. Mehta,<sup>1,2</sup> Stella M. Davies<sup>1,2</sup> and Kasiani C. Myers<sup>1,2</sup>

<sup>1</sup>Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center; <sup>2</sup>Department of Pediatrics, University of Cincinnati College of Medicine; <sup>3</sup>Division of Endocrinology, Cincinnati Children's Hospital Medical Center and

<sup>4</sup>Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH USA

Correspondence:

J. KOO - jane.koo@cchmc.org

<https://doi.org/10.3324/haematol.2024.285612>

**Supplemental table 1. Transplant characteristics of patients with FA who received HSCT**

	<b>HSCT</b> (n=63)
<b>Age at first HSCT in years, median (IQR)</b>	8.8 (6.3-10.6)
<b>Donor type, n (%)</b>	
Related	6 (10)
Unrelated	57 (90)
<b>Degree of match, n (%)</b>	
Fully matched	40 (63)
Mismatched	23 (37)
<b>Stem cell source, n (%)</b>	
Bone marrow	1 (1.6)
Peripheral blood stem cell	61 (97)
Cord	1 (1.6)
<b>Conditioning regimen, n (%)</b>	
Myeloablative	63 (100)
Reduced intensity	0
<b>GVHD prophylaxis, n (%)</b>	
CNI-based	24 (38)
T-cell depletion	39 (62)
<b>Acute GVHD score at day 100, n (%)</b>	
Grade I	2 (3.2)
Grade II	0

CNI: calcineurin inhibitor; GVHD: graft-vs-host-disease